BGI•RESEARCH
2.6.2022 10:02:10 CEST | Business Wire | Press release
International scientists led by China’s BGI•Research released the world’s first panoramic spatial atlases of life on May 4, examining the cellular dynamics of organisms at different developmental stages and providing potentially significant new information for disease treatment, development and aging, and an improved understanding of biological evolution.
In a series of studies published in Cell Press journals, members of the Spatio-Temporal Omics Consortium (STOC), an international scientific consortium, used the BGI-developed spatially resolved transcriptomics technology Stereo-seq to produce spatio-temporal cellular maps of mice, Drosophila , zebrafish and the Arabidopsis (thale cress) plant.
The papers demonstrate how Stereo-seq has achieved a major breakthrough in spatial resolution and panoramic field of view, enabling analysis of the distribution and placement of molecules and cells in situ, and over time.
Over 80 scientists from leading universities in 16 countries have so far collaborated as part of STOC focusing on using spatially resolved, cellular resolution omics technologies to map and understand life.
Spatial transcriptomics technology resolves previous issues identifying characteristics of single cells within a biological tissue. It builds on the achievements of single-cell sequencing, elevating it to the next level by enabling scientists to track a cell’s precise location and how it interacts with neighbouring cells.
Scientists used Stereo-seq to examine the early embryonic development of mice, particularly from 9.5 to 16.5 days, during which embryonic development is occurring at a fast rate. Stereo-seq generated the Mouse Organogenesis Spatiotemporal Transcriptomic Atlas (MOSTA), which maps with single-cell resolution and high sensitivity, the kinetics and directionality of transcriptional variation during mouse organogenesis.
“Stereo-seq is a transformational breakthrough in spatial transcriptomics technology and is the most powerful technology in this field of life sciences today,” said Dr. Liu Longqi of BGI•Research, one of the papers’ corresponding authors. “We now have the technology to map a panoramic atlas of every cell in an organism, according to their individual biomolecular profiles, in space and over time.”
“The successful application of our Stereo-seq technology for development has significant implications for the future of genomic research on human diseases,” said co-corresponding author Dr. Xu Xun, director of BGI•Research. “Demonstrating that this technology can pinpoint certain cells that indicate future disease will be critical for diagnostics and therapeutics for a number of conditions.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005196/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI27.4.2026 10:00:00 CEST | Press release
Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operati
First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 08:00:00 CEST | Press release
First enterprise quantum computer purchase in Japan cements IQM's position as the global leader in deployed quantum computers The Radiance 20-qubit system will enable TOYO to explore various industry use cases, while advancing a hybrid quantum-HPC infrastructure. This will be the third quantum computer to be deployed by IQM in the Asia-Pacific region. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
